A Phase 1 Study of Anti-Human EGFR (Vectibix Sequence) Targeted EDVs Carrying the Cytotoxic Drug PNU-159682 (EGFR-VEDVsPNU) with Concurrent Non-Targeted EDVs Carrying an Immunomodulatory Adjuvant (EDVs40-mer) in Subjects with Advanced Solid Tumours who have No Curative Treatment Options
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2017
At a glance
- Drugs PNU 159682 (Primary) ; Adjuvants
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms Designer EDV / ENG8
- Sponsors EnGeneIC
- 17 Oct 2017 Planned initiation date changed from 1 Apr 2017 to 19 May 2017.
- 17 Oct 2017 Status changed from recruiting to discontinued.
- 28 Jun 2017 Status changed from not yet recruiting to recruiting.